relapsing-remitting multiple sclerosis
Neurology · 2007–2020
5decisions
3medicines
2carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| ozanimod Treatment of clinically definite relapsing-remitting multiple sclerosis (RRMS). | Mar 2020 | Deferred | input received MS Australia |
| natalizumab Clinically-definite relapsing-remitting multiple sclerosis (RRMS). The submission sought to remove age restrictions from the existing PBS listing to permit… | Jul 2019 | Recommended | input received MS Australia · MS Research Australia |
| daclizumab Treatment of relapsing-remitting multiple sclerosis (RRMS). The submission sought a General Schedule Authority Required listing, with treatment restricted to… | Nov 2016 | Recommended | none received |
| natalizumab initial and continuing treatment, by neurologists, of clinically definite relapsing-remitting multiple sclerosis (RRMS) in ambulatory patients eighteen years… | Nov 2007 | Recommended | no section in document |
| natalizumab Initial and continuing treatment of clinically definite relapsing-remitting multiple sclerosis (RRMS) in ambulatory patients 18 years of age or older who have… | Nov 2007 | Recommended with restriction | no section in document |
Who spoke
MS Australia · MS Research Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 3 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.